1

2
Kevin Rodzinak
Furuyama Hidetomo, Goto Yasuhiro, Kawanishi Nobuhiko, Layton Mark E, Mita Takashi, Naya Akira, Ogino Yoshio, Onozaki Yu, Rodzinak Kevin J, Sakamoto Toshihiro, Sanderson Philip E, Wang Jiabing: Inhibitors of akt activity. Merck & Co, Banyu Pharmaceutical, Furuyama Hidetomo, Goto Yasuhiro, Kawanishi Nobuhiko, Layton Mark E, Mita Takashi, Naya Akira, Ogino Yoshio, Onozaki Yu, Rodzinak Kevin J, Sakamoto Toshihiro, Sanderson Philip E, Wang Jiabing, Leff Matthew A, December 10, 2009: WO/2009/148916 (10 worldwide citation)

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory compounds and methods ...


3
Kevin Rodzinak
Philip E Sanderson, Mark E Layton, Kevin J Rodzinak: Inhibitors of AKT activity. Merck Sharp & Dohme, Matthew A Leff, Yong Zhao, David A Muthard, May 1, 2012: US08168652 (4 worldwide citation)

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


4
Stéphane De Lombaert
Stéphane De Lombaert, Michel Jose Emmanuel: Chymase inhibitors. Boehringer Ingelheim International, Michael P Morris, Anthony P Bottino, Usha R Patel, June 5, 2012: US08193214

Disclosed are small molecule inhibitors which are useful in treating various diseases and conditions involving chymase.


5

6
Andreas G Weichert
Jan Robert Schwark, Joachim Brendel, Heinz Werner Kleemann, Hans Jochen Lang, Andreas Weichert, Udo Albus, Wolfgang Scholz: Substituted cinnamic acid guanidides, a process for their preparation, their use as medicaments or diagnostic agents and medicaments comprising them. Hoechst Aktiengesellschaft, Finnegan Henderson Farabow Garrett & Dunner L, March 16, 1999: US05883133 (5 worldwide citation)

Compounds of the formula I ##STR1## are described in which at least one of the substituents R(1), R(2), R(3), R(4) and R(5) is a nitrogen-containing heterocyclic radical. They are outstanding cardiovascular therapeutic agents. They are obtained by reaction of a compound II ##STR2## with guanidine.


7

8
Andreas G Weichert
Heinz Werner Kleemann, Hans Jochen Lang, Jan Robert Schwark, Andreas Weichert, Wolfgang Scholz, Udo Albus: Substituted benzoylguanidines, their use as a medicament or diagnostic, and medicament containing them. Hoechst Aktiengesellschaft, Finnegan Henderson Farabow Garrett & Dunner L, February 17, 1998: US05719169 (3 worldwide citation)

The invention relates to benzoylguanidines of the formula I: ##STR1## to pharmaceutically acceptable salts of these compounds and to a process for preparing compounds of the formula I, which comprise reacting a compound of the formula II ##STR2## with guanidine. The compounds of the invention are su ...


9
Andreas G Weichert
Heinz Werner Kleemann, Joachim Brendel, Jan Robert Schwark, Andreas Weichert, Hans Jochen Lang, Udo Albus, Wolfgang Scholz: Sulfonylamino-substituted benzoylguanidines, a process for their preparation, their use as a medicament or diagnostic aid, and medicament containing them. Hoechst Aktiengesellschaft, Finnegan Henderson Farabow Garrett & Dunner L, January 5, 1999: US05856344 (1 worldwide citation)

Benzoylguanidines of the formula I ##STR1## in which R(1) to R(6) have the meanings stated in the claims, are antiarrhythmic pharmaceuticals which have excellent activity and a cardioprotective component and are highly suitable for the prophylaxis of infarcts and the treatment of infarcts, and for t ...


10
Vinayak Khairnar
Sonali Rudra, Nidhi Gupta, Lalit Kumar Baregama, Ritu Agarwal, Vinayak Vasantrao Khairnar, Mandadapu Raghu Ramaiah, Venkata P Palle, Sarala Balachandran, Atul Kondaskar, Manohar Salla, Abhijit Ray, Sunanda G Dastidar, Lalitha Vijaykrishnan: Pyrazolo (3, 4-B) pyridine derivatives as phosphodiesterase inhibitors. Ranbaxy Laboratories, April 16, 2013: US08420666

The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4/PDE type 7 inhibitors. Compounds disclosed herein having the structure of Formula 1: can be useful in the treatment, prevention, inhibition or suppression of CNS diseases, for example, ...